41results about How to "Effective treatment options" patented technology

The invention provides a fluorescence detection method for detecting bacterial drug resistance in an individual and a diagnostic kit / diagnostic reagent thereof. According to the fluorescence detection method, absorbance difference under the condition of different wavelengths is detected by using a fluorogenic substrate, which only can be degraded by broad spectrum beta lactamase, through double fluorescence signals and further the bacterial drug resistance of the individual or the biological sample of the individual can be detected. The detection method and the obtained detection kit based on the method can detect the 3rd and 4th generations of drug-resistance bacteria of cephalosporin, which cannot be detected by products available in the markets and can reach a detection value of 10<5>-10<8> drug-resistance bacteria, so that a market blank is filled in, more effective monitoring method and use guide are provided for the use of antibiotics in clinic, and extremely great practical values are achieved.

The invention provides a drug combination for tumor immunotherapy, which includes an effective amount of an acyl-CoA:cholesterol acyl transferase ACAT1 inhibitor and an effective amount of an immune checkpoint blocking antibody. The present invention further provides a combination drug method for tumor immunotherapy. The present invention finds that inhibiting acyl-CoA:cholesterol acyltransferase ACAT1 can enhance the tumor-killing activity of CD8 T cells, and in combination with immune checkpoint blocking antibodies, the two can have a synergistic effect, and can further enhance the anti-tumor activity. inhibition.

The invention discloses a method and device for measuring morphological parameters of an intracranial aneurysm image. The method includes constructing a three-dimensional model including a parent artery and an aneurysm on the parent artery according to intracranial image data. The three-dimensional model includes The virtual parent artery matched with the parent artery and the virtual aneurysm matched with the aneurysm; the neck plane of the virtual aneurysm is determined based on the three-dimensional model, and the target morphological parameters are determined based on the three-dimensional model and the neck plane. The morphological parameters include at least morphological parameters of the virtual aneurysm. It can be seen that the implementation of the present invention automatically measures the morphological parameters of intracranial aneurysms through the three-dimensional model of intracranial image data and the neck plane of the virtual aneurysm included in the three-dimensional model, which can not only improve the measurement of the morphological parameters of intracranial aneurysms The accuracy of the results can improve the measurement speed of the morphological parameters of intracranial aneurysms, thereby providing scientific reference for medical staff when making treatment decisions.

The invention relates to a chimeric antigen receptor targeting BCMA, which comprises an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, wherein the extracellular domain is an anti-BCMA single domain antibody; wherein the amino acid sequence of the anti-BCMA single domain antibody is selected from: (a) an amino acid sequence as shown in SEQ ID NO. 1; or (b) a variant which is formed by substitution, addition or deletion of one or more amino acids in the amino acid sequence shown in SEQ ID NO. 1 and which is capable of specifically binding to the chimeric antigen receptor and has a function of binding to BCMA and inducing T cell signaling conduction. The chimeric antigen receptor has smaller clinical side effects and highersafety, can effectively reduce solid tumor focus and effectively improve the treatment effect of tumors.